Off Script: A Pharma Manufacturing Podcast

Pharma Manufacturing
  • 5,0 (5)
  • ДЕЛОВЫЕ НОВОСТИ
  • ЕЖЕНЕДЕЛЬНО
Off Script: A Pharma Manufacturing Podcast

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more. Off Script is hosted by Pharma Manufacturing editors Karen Langhauser and Meagan Parrish.

  1. 6 НОЯБ.

    MilliporeSigma expands ADC manufacturing, EU fines Teva, AZ exec under investigation in China [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — MilliporeSigma expands ADC manufacturing  The bad — EU fines Teva The ugly — AZ exec under investigation

    3 мин.

  2. 30 ОКТ.

    [Extended Release] Antibiotic resistance crisis and the global efforts against superbugs

    Join senior editor Andrea Corona and Emily Wheeler, Director of Infectious Disease Policy at the Biotechnology Innovation Organization (BIO), as they discuss the urgency of tackling antimicrobial resistance and the coordinated global efforts needed to save the struggling market of antibiotics.  Extended Release is an Off Script series to revisit conversations with our sources and explore new developments, gain deeper insights, and provide updates on the impact of their work.

    15 мин.

  3. 28 ОКТ.

    Nucleus RadioPharma expands production with new sites, FDA issues CRL to Camurus' hormone disorder drug, NHS rejects Eli Lilly's Alzheimer's drug over cost [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Nucleus RadioPharma expands production with new sites  The bad — FDA issues CRL to Camurus' hormone disorder drug  The ugly — NHS rejects Alzheimer's drug over cost concerns

    3 мин.

  4. 21 ОКТ.

    FDA approves AbbVie 24-hour Parkinson’s treatment, Sage Therapeutics axes workforce, FDA halts Novavax's COVID-flu vax trials [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA approves AbbVie 24-hour Parkinson’s treatment  The bad — Sage Therapeutics axes workforce  The ugly — FDA halts Novavax's COVID-flu vaccine trials

    3 мин.

  5. 14 ОКТ.

    Roche gets FDA nod for breast cancer combo, Kezar’s lupus drug trial on hold, Zealand Pharma’s hypoglycemia drug rejected over manufacturing [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Roche snags breast cancer FDA nod  The bad — FDA places clinical hold on Kezar lupus nephritis drug trial  The ugly — FDA rejects Zealand Pharma hypoglycemia drug over manufacturing reinspection

    3 мин.

  6. 7 ОКТ.

    Gilead inks deal with generics manufacturers to expand HIV drug access, J&J announces layoffs, Amgen sued for hiding $10.7B tax bill [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Gilead inks deal with generics manufacturers to expand HIV drug access  The bad — J&J announces layoffs at New Brunswick headquarters  The ugly — Amgen sued for hiding $10.7B tax bill

    4 мин.

  7. 30 СЕНТ.

    FDA approves BMS schizophrenia drug, bluebird bio announces layoffs, J&J talc subsidiary files for bankruptcy [The good, the bad, the ugly]

    Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good —FDA approves BMS schizophrenia drug  The bad — bluebird bio announces layoffs  The ugly —J&J talc subsidiary files for bankruptcy

    4 мин.

  8. 26 СЕНТ.

    [Extended Release] Schizophrenia treatment barriers, KarXT, and the future of neuroscience

    Join senior editor Andrea Corona and Sam Clark, CEO and founder of Terran Biosciences, for a discussion on KarXT's landmark approval, schizophrenia treatment barriers, prodrugs, and more.  Extended Release is an Off Script series that allows us to revisit conversations with our sources to explore new developments, gain deeper insights, and provide updates on the impact of their work. Each episode goes beyond the initial story, offering a richer understanding of key topics and ongoing innovations in the pharma industry.

    17 мин.
См. все (68)

Оценки и отзывы

5
из 5
Оценок: 5

Об этом подкасте

The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more. Off Script is hosted by Pharma Manufacturing editors Karen Langhauser and Meagan Parrish.

Информация

  • Автор
    Pharma Manufacturing
  • Годы выхода
    2020 - 2024
  • Выпуски
    68
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © Copyright 2020 All rights reserved.
  • Сайт подкаста
    Off Script: A Pharma Manufacturing Podcast

Вам может также понравиться

Чтобы прослушивать выпуски с ненормативным контентом, войдите в систему.

Следите за новостями подкаста

Войдите в систему или зарегистрируйтесь, чтобы следить за подкастами, сохранять выпуски и получать последние обновления.
Выберите страну или регион

Африка, Ближний Восток и Индия

Азиатско-Тихоокеанский регион

Европа

Латинская Америка и страны Карибского бассейна

США и Канада